- Home
- TNXP vs RDHL Comparison
TNXP vs RDHL Comparison
Compare TNXP & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- RDHL
- Stock Information
- Founded
- TNXP 2007
- RDHL 2009
- Country
- TNXP United States
- RDHL Israel
- Employees
- TNXP N/A
- RDHL N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- TNXP Health Care
- RDHL Health Care
- Exchange
- TNXP Nasdaq
- RDHL Nasdaq
- Market Cap
- TNXP 19.5M
- RDHL 8.6M
- IPO Year
- TNXP N/A
- RDHL N/A
- Fundamental
- Price
- TNXP $0.32
- RDHL $6.65
- Analyst Decision
- TNXP Strong Buy
- RDHL
- Analyst Count
- TNXP 2
- RDHL 0
- Target Price
- TNXP $53.50
- RDHL N/A
- AVG Volume (30 Days)
- TNXP 216.7M
- RDHL 21.1K
- Earning Date
- TNXP 11-12-2024
- RDHL 01-10-2025
- Dividend Yield
- TNXP N/A
- RDHL N/A
- EPS Growth
- TNXP N/A
- RDHL N/A
- EPS
- TNXP N/A
- RDHL N/A
- Revenue
- TNXP $11,291,000.00
- RDHL $3,707,000.00
- Revenue This Year
- TNXP $64.71
- RDHL $224.90
- Revenue Next Year
- TNXP $24.49
- RDHL $82.69
- P/E Ratio
- TNXP N/A
- RDHL N/A
- Revenue Growth
- TNXP 183.05
- RDHL N/A
- 52 Week Low
- TNXP $0.12
- RDHL $6.00
- 52 Week High
- TNXP $14.08
- RDHL $38.50
- Technical
- Relative Strength Index (RSI)
- TNXP 51.87
- RDHL 42.65
- Support Level
- TNXP $0.31
- RDHL $6.33
- Resistance Level
- TNXP $0.72
- RDHL $7.00
- Average True Range (ATR)
- TNXP 0.17
- RDHL 0.47
- MACD
- TNXP -0.00
- RDHL -0.03
- Stochastic Oscillator
- TNXP 13.31
- RDHL 26.14
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.